Impact of response to thalidomide-, lenalidomide- or bortezomib-containing induction therapy on the outcomes of multiple myeloma patients undergoing autologous transplantation

Bone Marrow Transplantation

Volumn 47, Issue 1, 2012, Pages 146-148

  Awan, F T ^a   Osman, S ^b   Kochuparambil, S T ^a   Gibson, L ^b   Remick, S C ^b   Abraham, J ^b   Craig, M ^b   Jillella, A ^a   Hamadani, M ^b  

^a MEDICAL COLLEGE OF GEORGIA   (United States)

^b WEST VIRGINIA UNIVERSITY   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

BORTEZOMIB; CREATININE; CYCLOPHOSPHAMIDE; LENALIDOMIDE; MELPHALAN; RECOMBINANT GRANULOCYTE COLONY STIMULATING FACTOR; THALIDOMIDE;

ADULT; AGED; CANCER STAGING; CANCER SURVIVAL; CHEMOSENSITIVITY; CONTROLLED STUDY; CREATININE BLOOD LEVEL; DRUG DOSE INCREASE; FEMALE; HUMAN; INDUCTION CHEMOTHERAPY; LETTER; LEUKEMIA REMISSION; MAJOR CLINICAL STUDY; MALE; MULTIPLE MYELOMA; OVERALL SURVIVAL; PERIPHERAL BLOOD STEM CELL; PERIPHERAL BLOOD STEM CELL TRANSPLANTATION; PRIORITY JOURNAL; PROGRESSION FREE SURVIVAL; TREATMENT OUTCOME; TREATMENT RESPONSE;

ADULT; AGED; ANTINEOPLASTIC AGENTS; BORONIC ACIDS; FEMALE; FOLLOW-UP STUDIES; HUMANS; IMMUNOSUPPRESSIVE AGENTS; MALE; MIDDLE AGED; MULTIPLE MYELOMA; PERIPHERAL BLOOD STEM CELL TRANSPLANTATION; PYRAZINES; RETROSPECTIVE STUDIES; THALIDOMIDE; TRANSPLANTATION, AUTOLOGOUS;

EID: 84855736330     PISSN: 02683369     EISSN: 14765365     Source Type: Journal    
DOI: 10.1038/bmt.2011.18     Document Type: Letter

References (10)

1. Attal M, Harousseau JL, Stoppa AM, Sotto JJ, Fuzibet JG, Rossi JF et al. A prospective, randomized trial of autologous bone marrow transplantation and chemotherapy in multiple myeloma. Intergroupe Francais du Myelome. N Engl J Med 1996; 335: 91-97. (Pubitemid 26240110)
2. Harousseau JL, Palumbo A, Richardson PG, Schlag R, Dimopoulos MA, Shpilberg O et al. Superior outcomes associated with complete response in newly diagnosed multiple myeloma patients treated with nonintensive therapy: analysis of the phase 3 VISTA study of bortezomib plus melphalanprednisone versus melphalan-prednisone. Blood 2010; 116: 3743-3750.
3. Alexanian R, Dimopoulos MA, Delasalle KB, Hester J, Champlin R. Myeloablative therapy for primary resistant multiple myeloma. Stem Cells 1995; 13(Suppl 2): 118-121.
4. Barlogie B, Alexanian R, Dicke KA, Zagars G, Spitzer G, Jagannath S et al. High-dose chemoradiotherapy and autologous bone marrow transplantation for resistant multiple myeloma. Blood 1987; 70: 869-872. (Pubitemid 18027425)
5. Kumar S, Lacy MQ, Dispenzieri A, Rajkumar SV, Fonseca R, Geyer S et al. High-dose therapy and autologous stem cell transplantation for multiple myeloma poorly responsive to initial therapy. Bone Marrow Transplant 2004; 34: 161-167. (Pubitemid 39077108)
6. Singhal S, Powles R, Sirohi B, Treleaven J, Kulkarni S, Mehta J. Response to induction chemotherapy is not essential to obtain survival benefit from high-dose melphalan and autotransplantation in myeloma. Bone Marrow Transplant 2002; 30: 673-679. (Pubitemid 35446649)
7. Vesole DH, Crowley JJ, Catchatourian R, Stiff PJ, Johnson DB, Cromer J et al. High-dose melphalan with autotransplantation for refractory multiple myeloma: results of a Southwest Oncology Group phase II trial. J Clin Oncol 1999; 17: 2173-2179. (Pubitemid 29318850)
8. Gertz MA, Kumar S, Lacy MQ, Dispenzieri A, Dingli D, Hayman SR et al. Stem cell transplantation in multiple myeloma: impact of response failure with thalidomide or lenalidomide induction. Blood 2010; 115: 2348-2353 quiz 2560.
9. Durie BG, Harousseau JL, Miguel JS, Blade J, Barlogie B, Anderson K et al. International uniform response criteria for multiple myeloma. Leukemia 2006; 20: 1467-1473. (Pubitemid 44264086)
10. Moreau P, Attal M, Pegourie B, Planche L, Hulin C, Facon T et al. Achievement of VGPR to induction therapy is an important prognostic factor for longer PFS in the IFM 2005-01 trial. Blood 2010 (e-pub ahead of print).